Short answer
LIGAND PHARMACEUTICALS INC (LGND) filed its Q3 2025 10-Q quarterly report on Nov 7, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $115M (up 122.8% year over year) with net income of $117M.
Q3 2025 key financials · XBRL
- Revenue
- $115M
- +122.8% YoY · +142.4% QoQ
- Net income
- $117M
- +1735.2% YoY · +2319.5% QoQ
- Operating margin
- 47.6%
- EPS (diluted)
- $5.90
- +1539.0% YoY · +2169.2% QoQ
Source: XBRL data from the LIGAND PHARMACEUTICALS INC (LGND) Q3 2025 10-Q on SEC EDGAR. USD.
LIGAND PHARMACEUTICALS INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Convertible Senior Notes $460M offering in Aug 2025 adds debt with 0.75% coupon due 2030, introducing dilution and interest expense risks
- Updated operational risk: Pelthos merger and divestiture yielding $53.1M income changes revenue profile and partnership dynamics notably in Q3 2025
- Regulatory risk: FDA updated REMS for Filspari reduces liver monitoring frequency and removes embryo-fetal toxicity monitoring, impacting product labeling compliance
- Market risk: Pelthos commercial launch of Zelsuvmi with 13% royalty exposure and milestone payments introduces sales revenue variability near term
- Financial risk: Liquidity strengthened by $445M net from convertible notes offering, with $46M used for convertible hedge reducing dilution risk
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LIGAND PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.